Common Contracts
9 similar Placement Agent Agreement contracts by Sunshine Biopharma, Inc, Bruush Oral Care Inc., Kaspien Holdings Inc., others
AEGIS CAPITAL CORP.Placement Agent Agreement • October 12th, 2023 • SciSparc Ltd. • Pharmaceutical preparations • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the lead placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by SciSparc Ltd. (collectively, with its subsidiaries and affiliates, the “Company”) of its ordinary shares, warrants, and pre-funded warrants (collectively, the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • May 22nd, 2023 • Volcon, Inc. • Motor vehicles & passenger car bodies • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the lead placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Volcon, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of Convertible Debt (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank. Each of Aegis and the Company are referred to herein as a “Party” and collectively as the “Parties.”
AEGIS CAPITAL CORP.Placement Agent Agreement • May 16th, 2023 • Sunshine Biopharma, Inc • Pharmaceutical preparations • New York
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units considered at the market under Nasdaq listing rules, with each unit consisting of one (1) share of common stock and two (2) warrants (“Warrants”), each to one (1) share of common stock exercisable at the Nasdaq at- the-market price of the common stock or consisting of one pre-funded warrant to purchase one (1) share of common stock and two (2) Warrants (collectively, the “Securities”). This placement agent agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company
AEGIS CAPITAL CORP.Placement Agent Agreement • February 22nd, 2023 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • New York
The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by OKYO Pharma Limited (collectively, with its subsidiaries and affiliates, the “Company”) of its American depositary shares (the “Securities”). This Agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • February 6th, 2023 • Sharps Technology Inc. • Surgical & medical instruments & apparatus • New York
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sharps Technology, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its securities (the “Securities”). This placement agent agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • December 20th, 2022 • Bruush Oral Care Inc. • Dental equipment & supplies • New York
The purpose of this placement agent agreement (this “Agreement”) is to set forth our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the lead placement agent on a best efforts basis in connection with the proposed private placement (the “Placement”) by Bruush Oral Care Inc. of its securities (the “Securities”). This Agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • July 14th, 2022 • Kaspien Holdings Inc. • Retail-record & prerecorded tape stores • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the lead placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Kaspien Holdings Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common stock (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • April 28th, 2022 • Sunshine Biopharma, Inc • Services-commercial physical & biological research • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units considered at the market under Nasdaq listing rules, consisting of one (1) share of common stock and two warrants to purchase shares of common stock exercisable at the unit offering price (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • March 15th, 2022 • Sunshine Biopharma, Inc • Services-commercial physical & biological research • New York
The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units consisting of one (1) share of common stock and one (1) warrant to purchase shares of common stock (the “Securities”). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
